Personalized DC Vaccine for Postoperative Cancer

Recruiting now · Phase 1

Conditions studied: Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer

In brief

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Key facts

Study ID

NCT04147078

Run by

Sichuan University

People needed

80

Starts

2019-06-01

Expected to finish

2026-06-01

Last updated by the study team

2025-02-28

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
• Anticipated life time > 3month
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
• Adequate organ functions

You may not qualify if…

• Any evidence of tumor metastasis or co-existing malignant disease
• Tumor emergency
• Abnormal coagulation condition
• Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
• Concomitant tumors
• Immunological co-morbidities

Where it is running

• Qiu Li — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.